Immune thrombocytopenia (itp)
Drug research and approvals for immune thrombocytopenia (itp): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 90 studies of immune thrombocytopenia (itp) are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 8 approved and 14 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 90
- Trials authorized in Canada: 7
- FDA orphan approvals: 8
- EU medicines: 6
Recruiting Now
Newest start dates first, of 90 recruiting on ClinicalTrials.gov ↗- TGD001 Treatment in Thrombotic MicroangiopathiesNCT07459114 · Phase 1 / Phase 2 · TargED Biopharmaceuticals B.V. · starts Oct 25, 2026
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary…NCT07700238 · Phase 3 · Amgen · starts Aug 21, 2026
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC…NCT07421167 · Phase 2 · Novartis Pharmaceuticals · starts Aug 4, 2026
- Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseaseNCT07549698 · Phase 1 / Phase 2 · CRISPR Therapeutics AG · starts Jul 17, 2026
- A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With…NCT07587723 · Not reported · Novartis Pharmaceuticals · starts Jun 25, 2026
- Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune…NCT07788456 · Phase 4 · Institute of Hematology & Blood Diseases Hospital, China · starts Jun 22, 2026
- SG301-SC Injection Safety Study in Subjects With Primary ITP PatientsNCT07710248 · Phase 2 · Hangzhou Sumgen Biotech Co., Ltd. · starts Jun 11, 2026
- Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune ThrombocytopeniaNCT07657793 · Phase 2 / Phase 3 · Chinese SLE Treatment And Research Group · starts Jun 7, 2026
- Safety and Efficacy of GL-2045 in Patients With Immune ThrombocytopeniaNCT07605845 · Phase 1 · Gliknik Inc. · starts Apr 14, 2026
- High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult…NCT07559331 · Phase 3 · Shandong University · starts Apr 8, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Nov 5, 2021 | An interventional phase 2, open-label, one-arm, multicenter study to evaluate safety and efficacy of pf-06835375 in adult participants with moderate to severe…PF-06835375 | Pfizer | Closed |
| Dec 1, 2020 | A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension to evaluate the efficacy and safety of…RILZABRUTINIB (PRN1008) | PRINCIPIA BIOPHARMA INC | Ongoing |
| Apr 28, 2020 | A phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of rozanolixizumab in adult study…ROZANOLIXIZUMAB (UCB7665) | UCB | Closed |
| Feb 21, 2019 | An adaptive, open-label, dose-finding, phase 1/2 study investigating the safety, pharmacokinetics, and clinical activity of rilzabrutinib (prn1008), an oral…RILZABRUTINIB (PRN1008) | PRINCIPIA BIOPHARMA INC | Closed |
| Nov 4, 2014 | A single arm, open-label, long-term efficacy and safety study of romiplostim in thrombocytopenic pediatric subjects with immune thrombocytopenia (itp)NPLATE (ROMIPLOSTIM) | Amgen | Ongoing |
| Oct 10, 2014 | Open label, adaptive design, ascending, multiple-dose study to evaluate safety and efficacy of bms-986004 (anti-cd40l dab) in adult subjects with primary…BMS 986004 (ANTI-CD40L DOMAIN ANTIBODY) | Bristol-Myers Squibb | Ongoing |
| Sep 18, 2013 | A rollover study to provide continued treatment with eltrombopagREVOLADE | GSK | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 22| Aug 29, 2025 | Wayrilztreatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous… | Genzyme Corporation (A Sanofi Company) | Approved |
| Jul 24, 2025 | Doptelettreatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an… | Sobi, Inc. | Approved |
| Oct 17, 2019 | NplateNplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient… | Amgen, Inc. | Approved |
| Jun 26, 2019 | avatrombopag maleateDOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an… | Sobi, Inc. | Approved |
| Dec 14, 2018 | NplateNplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who… | Amgen, Inc. | Approved |
| Apr 17, 2018 | fostamatinib disodium hexahydrateTAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an… | Rigel Pharmaceuticals, Inc. | Approved |
| Mar 8, 2013 | GammaplexIdiopathic thrombocytopenic purpura | Bio Products Laboratory | Approved |
| Aug 22, 2008 | NplateTreatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient… | Amgen, Inc. | Approved |
| Oct 24, 2026 | sovleplenib acetatetreatment of primary immune thrombocytopenia | HUTCHMED Limited | Designated |
| Aug 22, 2026 | pirtobrutinibtreatment of primary immune thrombocytopenia | Eli Lilly and Company | Designated |
| Dec 4, 2025 | bispecific humanized IgG4 BCMA-directed CD3 T cell engager…treatment of immune thrombocytopenia (ITP) | Lakefront Biotherapeutics West LLC | Designated |
| Feb 13, 2025 | Ianalumabtreatment of primary immune thrombocytopenia | Novartis Pharmaceutical Corporation | Designated |
| Dec 16, 2024 | rituximabtreatment of immune thrombocytopenia | ODDIFACT SAS | Designated |
| Jul 31, 2024 | recombinant human thrombopoietin (rhTPO)treatment of primary immune thrombocytopenia (ITP) | 3SBIO Inc. (Shenyang Sunshine Pharmaceuticals CO., Ltd.) | Designated |
| Mar 20, 2024 | CevidoplenibTreatment of primary immune thrombocytopenia (ITP) | Oscotec Inc. | Designated |
Medicines Authorised in the EU
Newest first| Dec 22, 2025 | Wayrilzrilzabrutinib · orphan | Sanofi B.V. | EMA ↗ |
| Mar 28, 2025 | Eltrombopag Accordeltrombopag · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Dec 12, 2024 | Eltrombopag Viatriseltrombopag · generic | Viatris Limited | EMA ↗ |
| Jan 9, 2020 | Tavlessefostamatinib | Instituto Grifols S.A. | EMA ↗ |
| Mar 11, 2010 | Revoladeeltrombopag | Novartis Europharm Limited | EMA ↗ |
| Feb 4, 2009 | Nplateromiplostim | Amgen Europe B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA